Acrivon Therapeutics Statistics
Total Valuation
ACRV has a market cap or net worth of $81.27 million. The enterprise value is -$102.17 million.
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025, before market open.
Earnings Date | May 13, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
ACRV has 31.14 million shares outstanding. The number of shares has increased by 54.55% in one year.
Current Share Class | 31.14M |
Shares Outstanding | 31.14M |
Shares Change (YoY) | +54.55% |
Shares Change (QoQ) | +5.46% |
Owned by Insiders (%) | 6.84% |
Owned by Institutions (%) | 29.48% |
Float | 11.06M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.41 |
P/TBV Ratio | 0.41 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.75, with a Debt / Equity ratio of 0.02.
Current Ratio | 12.75 |
Quick Ratio | 12.65 |
Debt / Equity | 0.02 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -45.95% and return on invested capital (ROIC) is -31.04%.
Return on Equity (ROE) | -45.95% |
Return on Assets (ROA) | -29.15% |
Return on Invested Capital (ROIC) | -31.04% |
Return on Capital Employed (ROCE) | -42.68% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.26M |
Employee Count | 61 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.24% in the last 52 weeks. The beta is 0.86, so ACRV's price volatility has been lower than the market average.
Beta (5Y) | 0.86 |
52-Week Price Change | -58.24% |
50-Day Moving Average | 5.48 |
200-Day Moving Average | 6.93 |
Relative Strength Index (RSI) | 24.13 |
Average Volume (20 Days) | 119,031 |
Short Selling Information
The latest short interest is 1.13 million, so 3.64% of the outstanding shares have been sold short.
Short Interest | 1.13M |
Short Previous Month | 1.10M |
Short % of Shares Out | 3.64% |
Short % of Float | 10.24% |
Short Ratio (days to cover) | 19.11 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -85.30M |
Pretax Income | -64.12M |
Net Income | -76.98M |
EBITDA | -84.45M |
EBIT | -85.30M |
Earnings Per Share (EPS) | -$2.58 |
Full Income Statement Balance Sheet
The company has $187.45 million in cash and $4.01 million in debt, giving a net cash position of $183.44 million or $5.89 per share.
Cash & Cash Equivalents | 187.45M |
Total Debt | 4.01M |
Net Cash | 183.44M |
Net Cash Per Share | $5.89 |
Equity (Book Value) | 196.89M |
Book Value Per Share | 6.32 |
Working Capital | 174.17M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$60.68 million and capital expenditures -$3.09 million, giving a free cash flow of -$63.77 million.
Operating Cash Flow | -60.68M |
Capital Expenditures | -3.09M |
Free Cash Flow | -63.77M |
FCF Per Share | -$2.05 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |